{"filings":[{"id":94007,"accession_number":"0001601830-26-000077","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion Q1 net loss narrows to $117.5M; REC-1245 safety data positive, REC-4539 dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $117.5M vs $202.5M YoY; revenue $6.5M, down 56% YoY on lower Roche milestone phasing.","Cash & equivalents $665.2M; 2026 cash burn guidance <$390M, runway into early 2028 without financing.","REC-1245 (RBM39 degrader): No DLTs in 16 patients; well-tolerated with dose-dependent PK; dose escalation ongoing.","REC-4881 (MEK1/2) in FAP: 43% median polyp burden reduction at Week 13; FDA engagement for registrational path begun.","REC-4539 (LSD1 inhibitor): First patient dosed in Phase 1 ENLYGHT study; reversible design to reduce platelet toxicity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":6472000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94006,"accession_number":"0001601830-26-000064","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Recursion founder & Chair Chris Gibson will not stand for re-election; to become advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chris Gibson, Ph.D., founder and Chair, will not seek re-election at 2026 Annual Meeting (June 2026).","He will continue as Chair until term ends, then serve as strategic advisor to the company.","Gibson stated decision not due to any disagreement with Recursion on operations, policies, or practices.","CEO Najat Khan thanked Gibson, emphasizing continuity, pipeline progress, and long-term value creation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106050,"accession_number":"0001601830-26-000054","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Recursion appoints Vicki Goodman as CMO effective April 6, 2026; David Mauro transitions out","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Goodman joins from Mural Oncology as CMO; prior executive roles at Exelixis, Merck, BMS, and GSK.","Outgoing CMO Dr. Mauro will serve as advisor until May 29, 2026, after three years at Recursion.","CEO Najat Khan highlights Goodman's late-stage clinical development experience for advancing pipeline.","Company reiterates key clinical and regulatory milestones consistent with prior expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106049,"accession_number":"0001601830-26-000038","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion Q4 revenue $35.5M; first AI-driven clinical validation in FAP; cash runway to 2028","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $35.5M (up from $4.5M YoY); net loss $108.1M vs $178.9M; cash $753.9M.","REC-4881 (MEK1/2) in FAP: 75% evaluable patients had reduced polyp burden at 12 weeks; 43% median reduction.","Fifth Sanofi milestone ($4M) achieved Feb 2026; total $134M milestone payments received from Sanofi.","2026 cash operating expense guidance <$390M; cash runway into early 2028 without additional financing.","REC-7735 (PI3Kα H1047R) shows >100-fold selectivity over WT; IND-enabling studies ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":74681000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106048,"accession_number":"0001601830-26-000002","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Recursion releases updated investor presentation for JP Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated January 12, 2026, used at JP Morgan Healthcare Conference and investor meetings.","Slide mentions 'Maintaining ambition while raising the bar' message; no detailed financial or pipeline updates disclosed.","No specific material operational, financial, or strategic changes reported in the filing.","Presentation is furnished under Item 7.01 and not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122341,"accession_number":"0001601830-25-000174","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion reports positive Phase 1b/2 data for REC-4881 in FAP: 75% show polyp burden reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["75% of evaluable patients reduced total polyp burden at 12 weeks; median reduction 43%.","At 25 weeks (12 weeks off therapy), 82% maintained reduction with 53% median decrease from baseline.","40% of patients achieved ≥1-point improvement in Spigelman stage (upper GI disease severity).","Safety profile consistent with MEK1/2 inhibition; no Grade ≥4 TRAEs reported to date.","Company to engage FDA in 1H26 for registration pathway; trial expanding to ages ≥18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122340,"accession_number":"0001601830-25-000172","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion issues 7.1M shares to Tempus AI for license fees; registers for resale","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,088,742 Class A shares to Tempus AI on Nov 24, 2025 as payment for annual license fees.","Shares registered for resale via prospectus supplement filed Nov 26, 2025 under existing shelf registration.","Issuance stems from Master Agreement dated Nov 9, 2023, as previously disclosed in an 8-K.","Resale registration may allow Tempus to sell shares, creating potential dilution for existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122339,"accession_number":"0001601830-25-000164","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Recursion appoints Najat Khan as CEO effective Jan 1, 2026; Q3 net loss $162.3M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Najat Khan succeeds Chris Gibson as CEO and President effective Jan 1, 2026; Gibson becomes Chairman.","Khan's base salary set at $680K; receives $1M equity now and expected additional $7.5M equity.","Q3 revenue $5.2M (down from $26.1M); net loss $162.3M (vs $95.8M); R&D spend $121.1M.","Cash ~$785M as of Oct 9, 2025; runway through end-2027; raised $387.5M from ATM facility.","Second microglia phenomap accepted by Roche/Genentech triggers $30M milestone; total partner payments exceed $500M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122338,"accession_number":"0001601830-25-000152","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Roche exercises option for Recursion's Microglia Map; $30M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche exercised option for a first-of-its-kind whole genome map of brain immune cells (Microglia Map) from Recursion.","Recursion will receive a $30 million Acceptance Fee from Roche under the 2021 Collaboration and License Agreement.","The Microglia Map is generated by Recursion's platform as part of the ongoing partnership with Roche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139044,"accession_number":"0001601830-25-000142","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K/A","filed_at":"2025-08-29T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Recursion issues 2.4M contingent shares to Rallybio after GLP tox milestone","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Milestone triggered by initiation of GLP toxicology study on August 25, 2025.","Issued 2,397,023 contingent shares at $5.2148/share, representing $12.5M value.","Shares issued to Rallybio as seller under July 2025 ENPP1 JV acquisition.","Prospectus supplement filed August 29, 2025 to register shares for resale.","Filing amends prior 8-K from July 8, 2025 regarding the original acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139046,"accession_number":"0001601830-25-000126","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Announced $7 million milestone from Sanofi partnership for partnered discovery program.","REC-1245 (RBM39) DAHLIA Phase 1/2 trial enrolling patients with tumors exhibiting replication stress and DDR vulnerabilities.","REC-617 (CDK7 inhibitor) combination cohort to target platinum-resistant ovarian cancer using multi-omic and causal AI.","Co-founder and CEO Chris Gibson highlighted platform advancements including Boltz-2 for ligand design.","Exhibit text truncated; specific Q2 revenue, EPS, and cash position figures were not provided in the available excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":33968000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139045,"accession_number":"0001193125-25-156440","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["3.02","7.01","8.01","9.01"],"status":"ready","headline":"Recursion acquires full ownership of oral ENPP1 inhibitor program from Rallybio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Buys Rallybio's 50% stake in ENPP1 JV, gaining full rights to REV102 for hypophosphatasia.","Initial consideration: 1,457,952 RXRX shares (~$7.5M at $5.1442 VWAP) plus cash.","Contingent milestone payments up to $12.5M in additional shares.","REV102 is a preclinical oral ENPP1 inhibitor for rare bone disorder HPP.","Deal closed July 8, 2025; resale registration filed for issued shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156561,"accession_number":"0001601830-25-000088","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Recursion Pharmaceuticals stockholders elect directors, approve exec comp, ratify auditor at 2025 meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Zachary Bogue (242.3M for, 4.0M withheld), Zavain Dar (203.3M for, 42.9M withheld), Robert Hershberg (233.5M for, 12.8M withheld) as Class I directors.","Advisory resolution to approve executive compensation approved with 239.9M for, 3.2M against, 3.1M abstain, 93.4M broker non-votes.","Ratification of PwC as independent auditor for FY2025 approved with 334.6M for, 2.0M against, 3.1M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156560,"accession_number":"0001193125-25-138138","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.","Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.","Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.","Reduction part of streamlined operating strategy and post-integration transitions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156559,"accession_number":"0001193125-25-116989","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion registers 4.26M shares for resale by Tempus Labs under prior license agreement","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement to register 4,260,927 shares of Class A common stock for resale by Tempus Labs, Inc.","Shares were issued as payment for annual license fees under a Master Agreement dated Nov 2023.","Offering made under an exemption from registration; legal opinion filed as Exhibit 5.1.","Registration does not involve new issuance of shares; existing shares held by Tempus."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156558,"accession_number":"0001601830-25-000074","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion Q1 net loss widens to $202.5M; Sanofi milestone $7M; pipeline refocused","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss $202.5M vs $91.4M YoY; revenue $15M (up from $14M).","Cash & equivalents $509M; projected cash runway into mid-2027; 2025 cash burn ≤$450M.","Achieved 4th Sanofi milestone, $7M payment; total Sanofi cash inflow $130M to date.","Deprioritized 3 clinical programs (REC-2282, REC-994, REC-3964) to focus on oncology and rare disease.","REC-4881 preliminary data: median 43% polyp burden reduction in FAP Phase 1b/2 study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":14745000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174979,"accession_number":"0001601830-25-000040","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Recursion appoints former FDA Principal Deputy Commissioner Dr. Bumpus and Mammoth Biosciences COO/CFO Sun to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elaine Sun and Dr. Namandjé Bumpus appointed to Board effective March 15, 2025, expanding board from 8 to 10.","Dr. Bumpus served as FDA Principal Deputy Commissioner until Dec 2024, brings regulatory and AI-in-science expertise.","Elaine Sun is COO/CFO of Mammoth Biosciences, ex-CFO of Halozyme, with 30 years life sciences finance experience.","New committees: R&D and Technology; Sun chairs Audit, Bumpus joins Nominating, R&D, and Technology committees.","Director compensation policy amended to cover new committee roles."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174978,"accession_number":"0001601830-25-000034","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion reports Q4 net loss $178.9M, FY2024 net loss $463.7M; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and restricted cash $603.0M at Dec 31, 2024 vs $401.4M at Dec 31, 2023; runway extended into 2027.","Q4 revenue $4.5M (down 59% YoY); FY2024 revenue $58.8M (up 32% YoY). Pro forma revenue $82.6M.","Operating cash outflow $115.4M in Q4; $359.2M for FY2024. Exscientia cash burn ~$184M pre-acquisition.","Completed Exscientia merger Nov 2024; maintaining guidance of at least $100M in annual synergies.","Pipeline advanced: REC-617 showed durable partial response; three new clinical trials initiated (DAHLIA, TUPELO, ALDER)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":58839000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174977,"accession_number":"0001601830-25-000008","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Recursion Pharmaceuticals releases updated investor presentation for JP Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Investor presentation dated January 13, 2025 attached as Exhibit 99.1","Presentation to be used at JP Morgan Healthcare Conference and in investor meetings","CEO Christopher Gibson signed the 8-K filing on January 13, 2025","Information furnished under Item 7.01 not deemed filed for SEC purposes"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191951,"accession_number":"0001601830-24-000245","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion registers 3.5M shares for resale by Tempus Labs as license fee payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Recursion filed prospectus supplement to register 3,498,393 shares for resale by Tempus Labs.","Shares were issued to Tempus as payment for 2024 annual license fee under Master Agreement dated Nov 2023.","Offering made under exemption from registration; no new issuance or capital raise for Recursion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191950,"accession_number":"0001601830-24-000232","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Recursion CFO Ben Taylor gets $5M equity grant, enhanced vesting on Exscientia awards","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ben Taylor (CFO) enters employment letter with Exscientia AI Ltd, base salary £400K/year.","Annual cash bonus target 25% of base salary; equity bonus target also 25%.","New equity grant of $5M (50% RSUs, 50% options) vesting over 4 years, subject to board approval.","Pre-existing Exscientia awards (Exchanged Awards) fully vest if terminated w/o cause or resign for good reason within 12 months of Nov 20, 2024 closing.","Employment requires 3 months' notice/pay in lieu; garden leave may offset severance plan benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191943,"accession_number":"0001601830-24-000229","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K/A","filed_at":"2024-11-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Recursion completes Exscientia acquisition; pro forma shows increased net losses","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price ~$635.9M; transaction closed Nov 20, 2024.","Pro forma 2023 net loss of $548.7M ($1.74/share) vs Recursion standalone $328.1M.","Pro forma 9M 2024 net loss of $476.5M ($1.32/share) vs Recursion standalone $284.8M.","Combined total assets ~$1.55B, equity ~$1.14B as of Sept 30, 2024.","Goodwill of $76.9M and intangible assets of $355.1M recorded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191942,"accession_number":"0001601830-24-000224","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K/A","filed_at":"2024-11-26T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Recursion issues 102.3M shares to close Exscientia acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["102,298,808 shares of Class A common stock issuable to Exscientia shareholders and option/RSU holders.","Shares issued in exchange for Exscientia ordinary shares and canceled equity awards under the Transaction Agreement.","Issuance exempt from registration under Securities Act Section 3(a)(10).","Transaction closed on November 20, 2024; this Amendment provides final share count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191949,"accession_number":"0001601830-24-000217","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["2.01","5.02","7.01","8.01","9.01","6.01"],"status":"ready","headline":"Recursion completes Exscientia acquisition; issues 102M shares, names new CFO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Exscientia effective Nov 20, 2024 via UK scheme; 0.7729 Recursion shares per Exscientia share; 102,138,419 shares issued.","Exscientia ADSs (EXAI) delisted from Nasdaq; equity awards converted to Recursion options/RSUs using Exchange Ratio.","CFO Michael Secora steps down; Ben Taylor (Exscientia's former CFO) appointed CFO of Recursion and President of Recursion UK.","COO Tina Marriott transitions to Executive Advisor; CEO Chris Gibson adds President role; David Hallet named CSO; other exec promotions.","Board expands to 8; Franziska Michor appointed Class II director. 2024 Inducement Equity Plan adopted, reserving 17.5M shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191948,"accession_number":"0001601830-24-000201","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Recursion shareholders approve stock issuance for Exscientia acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.","Proposal 2 (adjournment) deemed unnecessary after approval; not presented at Special Meeting.","Special Meeting held Nov 12, 2024; quorum achieved with 253.5M votes present (72.5% of total eligible)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191947,"accession_number":"0001601830-24-000199","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion & Exscientia shareholders approve combination; close expected Nov 20","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Overwhelming shareholder approval from both Recursion (RXRX) and Exscientia (EXAI) for the proposed combination.","Transaction expected to close on November 20, 2024, subject to remaining customary conditions.","Chris Gibson, Ph.D., to remain CEO of the combined company post-closing.","Update call on Nov 20 at 7:30 a.m. ET; details on X, LinkedIn, YouTube.","Final voting results to be filed via 8-K and 6-K with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191946,"accession_number":"0001601830-24-000195","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Recursion Q3 revenue $26.1M, net loss $95.8M; Exscientia merger on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue surged to $26.1M from $10.5M YoY; net loss $95.8M vs $93.0M; no EPS provided.","Cash and equivalents $427.6M as of Sep 30, 2024; net cash used in operations $59.2M.","Roche-Genentech optioned first neuroscience phenomap for $30M; total potential $500M across multiple maps.","Proposed Exscientia merger: shareholder vote Nov 12; scheme of arrangement expected Nov 20, 2024.","Clinical milestones: Phase 2 CCM data encouraging; IND cleared for REC-1245; first patient dosed in Phase 2 C. diff."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":54293000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191945,"accession_number":"0001104659-24-114487","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Recursion amends Exscientia acquisition to clarify post-closing board appointments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amendment lets Exscientia designate one board member (subject to Recursion board approval) effective at closing; a second member if mutually agreed.","Supplemental disclosures reveal deal discussions began Oct 2022 with an exploratory 'merger of equals' proposal between CEOs.","Disclosed Exscientia risk-adjusted revenue forecast: $18M (2024E) rising to $659M (2049E); Recursion revenue forecast $30M (2024E) to $627M (2049E).","Centerview DCF implied Exscientia equity value $3.90–$6.60 per share; analyst price targets gave implied exchange ratio range of 0.4118x–1.1250x (actual 0.7729x).","Recursion formed a Transaction Committee in July 2024 to oversee negotiations; no additional compensation or conflicts noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191944,"accession_number":"0001601830-24-000165","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.","Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.","Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.","Initially addressable population estimated at >100,000 patients in the US and EU5.","Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208403,"accession_number":"0001601830-24-000148","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).","Filed audited financials of Exscientia for FY2023 and FY2022 (Exhibit 99.3) and unaudited interim statements for H1 2024 (Exhibit 99.4).","Filed pro forma condensed combined balance sheet as of June 30, 2024 and pro forma statements of operations (Exhibit 99.5).","Transaction closing deadline Aug 8, 2025; termination fees: Recursion $58.77M, Exscientia $6.88M; subject to HSR, court, stockholder votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208402,"accession_number":"0001601830-24-000140","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Evotec commits ~11% Exscientia shares to Recursion deal; total committed ~53%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Evotec SE, holding ~11% of Exscientia shares, executed irrevocable undertaking on Aug 28 to vote in favor of Recursion acquisition.","Combined with prior undertakings from August 8, shareholders holding ~53% of Exscientia now committed to support the deal.","The transaction is structured as a scheme of arrangement under UK Companies Act, with Recursion acquiring all Exscientia share capital.","Irrevocable undertaking prohibits Evotec from accepting competing offers or taking actions that impede the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208401,"accession_number":"0001193125-24-196505","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["1.01","2.02","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Recursion acquires Exscientia in stock deal; director Burrell resigns; Q2 results reported","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Recursion to acquire Exscientia via UK scheme of arrangement; Exscientia shareholders get 0.7729 Recursion shares per share.","Termination fees: Exscientia pays $6.88M if it accepts a superior proposal; Recursion pays $58.77M if it walks.","Terry-Ann Burrell resigns from board effective Aug 12, 2024; Zachary Bogue appointed Audit Committee Chair.","Q2 2024 financial results announced; specific figures not provided in this filing but refer to press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208400,"accession_number":"0001601830-24-000110","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Recursion announces Roche exercises option for first Neuroscience Phenomap; receives $30M fee","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Roche exercised option for first Neuroscience Phenomap under 2021 Collaboration Agreement.","Recursion to receive $30 million Acceptance Fee from Roche.","Option exercised by Genentech, a member of the Roche Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226084,"accession_number":"0001601830-24-000091","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Recursion prices $200M public offering of 30.8M shares at $6.50 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$200M before underwriting discounts and estimated offering expenses.","Offering comprises 30,769,230 shares of Class A common stock at $6.50 per share.","Underwriters granted 30-day option to purchase up to additional 4,615,384 shares.","Expected closing date June 28, 2024, subject to customary conditions.","Goldman Sachs & Co. LLC and J.P. Morgan are lead book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226083,"accession_number":"0001601830-24-000085","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.","REC-3964 (C. diff) Phase 2 start Q4 2024; RBM39 IND Q3 2024; Target Epsilon IND early 2025.","Bayer first beta-user of LOWE platform; joint oncology project towards Lead Series nomination; 25 data packages Q3 2024.","ADME industrialization ~90x throughput over manual; genome-scale transcriptomics knockout map; 90% success predicting compound failures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226082,"accession_number":"0001601830-24-000076","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Recursion annual meeting elects Class III directors, approves say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Blake Borgeson, Ph.D. elected as Class III director with 165,914,956 votes for, 26,093,759 withheld.","Dean Y. Li, M.D., Ph.D. elected as Class III director with 166,211,058 votes for, 25,797,657 withheld.","Advisory resolution on executive compensation approved with 188,317,831 for, 2,887,180 against, 803,704 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226081,"accession_number":"0001601830-24-000065","cik":1601830,"company_name":"RECURSION PHARMACEUTICALS, INC.","ticker":"RXRX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["4.01","5.02","7.01","9.01"],"status":"ready","headline":"Recursion appoints Robert Hershberg as new board chair; Martin Chavez to exit at 2024 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Martin Chavez not standing for re-election; term ends at 2024 Annual Meeting; no disagreement with company.","Board elects Robert Hershberg as new Chair effective at 2024 Annual Meeting; board size reduced from 9 to 8.","Hershberg, board member since May 2020, is CEO of HilleVax and former Celgene executive with 25+ years experience.","Auditor changed to PricewaterhouseCoopers for FY 2024 engagement, as previously disclosed on May 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1719669535.1545742,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}